The researchers thus inhibited mTORC1, both genetically and with an approved drug called everolimus, and observed transient shrinkage of metastatic breast tumors in mice, while combined blockade of mTORC1 and RON delayed metastatic progression. Here, MST1R is linked to breast neoplasm.